Publications by authors named "Hussein Tawbi"

100Publications

Bullous Pemphigoid-like Eruption Triggered by Targeted Therapy for Metastatic Melanoma.

Acta Derm Venereol 2020 Sep 28. Epub 2020 Sep 28.

Oncology-Pathology and Department of Oncology/Skin Cancer Center, Theme Cancer, Karolinska Institutet, Karolinska University Hospital Solna, SE-176 76 Stockholm, Sweden. E-mail:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3648DOI Listing
September 2020

The standard of care for brain metastases in melanoma.

Authors:
Hussein Tawbi

Clin Adv Hematol Oncol 2020 Jan;18(1):28-31

Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
January 2020

"Liquid Gold" - The unTAPped Potential of Cerebrospinal Fluid Analysis?

Clin Cancer Res 2020 May 5;26(9):2083-2084. Epub 2020 Mar 5.

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-20-0173DOI Listing
May 2020

A promising start for checkpoint inhibitors in childhood malignancies.

Authors:
Hussein Tawbi

Lancet Oncol 2020 01 4;21(1):13-14. Epub 2019 Dec 4.

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30803-4DOI Listing
January 2020

Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities.

Proc Natl Acad Sci U S A 2019 10 14;116(44):22246-22251. Epub 2019 Oct 14.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1908079116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825284PMC
October 2019

The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018.

J Transl Med 2019 05 10;17(1):148. Epub 2019 May 10.

Clinical Trials Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-019-1892-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509811PMC
May 2019

Quantitation of paclitaxel, and its 6-alpha-OH and 3-para-OH metabolites in human plasma by LC-MS/MS.

J Pharm Biomed Anal 2019 Aug 15;172:26-32. Epub 2019 Apr 15.

Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, United States; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07317085183240
Publisher Site
http://dx.doi.org/10.1016/j.jpba.2019.04.027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548629PMC
August 2019

Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.

J Immunother Cancer 2019 04 24;7(1):113. Epub 2019 Apr 24.

Department of Medicine, University of Pittsburgh, UPMC Hillman Cancer Center, 5117 Centre Avenue, Suite 1.27, Pittsburgh, PA, 15213, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0552-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480917PMC
April 2019

Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).

J Neurooncol 2019 May 7;142(3):499-509. Epub 2019 Mar 7.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-019-03121-2DOI Listing
May 2019

PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy.

Sci Rep 2019 03 1;9(1):3309. Epub 2019 Mar 1.

Department of Melanoma Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-39542-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397203PMC
March 2019

Reply to A. Shinde et al.

J Clin Oncol 2019 04 26;37(12):1031-1032. Epub 2019 Feb 26.

Harriet M. Kluger, MD, Yale School of Medicine, New Haven, CT; Kim A. Margolin, MD, City of Hope, Duarte, CA; Michael A. Davies, MD, PhD, MD Anderson Cancer Center, Houston, TX; Georgina V. Long, PhD, The University of Sydney, Sydney, NSW, Australia; Hussein A. Tawbi, MD, PhD, MD Anderson Cancer Center, Houston, TX; and Sarah B. Goldberg, MD and Veronica L. Chiang, MD, Yale School of Medicine, New Haven, CT.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.02463
Publisher Site
http://dx.doi.org/10.1200/JCO.18.02463DOI Listing
April 2019

Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

N Engl J Med 2018 11;379(22):2178

City of Hope, Duarte, CA

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMc1812500
Publisher Site
http://dx.doi.org/10.1056/NEJMc1812500DOI Listing
November 2018

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.

J Clin Oncol 2018 Oct 25:JCO1800632. Epub 2018 Oct 25.

Diwakar Davar, Hong Wang, Joe-Marc Chauvin, Ornella Pagliano, Julien J. Fourcade, Mignane Ka, Carmine Menna, Amy Rose, Cindy Sander, Amir A. Borhani, Arivarasan Karunamurthy, John M. Kirkwood, and Hassane M. Zarour, University of Pittsburgh, Pittsburgh, PA ; Ahmad A. Tarhini, Cleveland Clinic, Cleveland, OH; Hussein A. Tawbi, The University of Texas MD Anderson Cancer Center, Houston, TX; and Qing Zhao, Blanca H. Moreno, Scott Ebbinghaus, and Nageatte Ibrahim, Merck, Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.00632
Publisher Site
http://dx.doi.org/10.1200/JCO.18.00632DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286160PMC
October 2018

New Era in the Management of Melanoma Brain Metastases.

Am Soc Clin Oncol Educ Book 2018 May;38:741-750

From The University of Texas MD Anderson Cancer Center, Houston, TX; Institut Gustave Roussy, Paris, France; Peter MacCallum Cancer Centre, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_200819DOI Listing
May 2018

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

N Engl J Med 2018 Aug;379(8):722-730

From the University of Texas M.D. Anderson Cancer Center, Houston (H.A.T.); Moffitt Cancer Center and Research Institute, Tampa, FL (P.A.F., N.I.K.); University of California-San Francisco, San Francisco (A. Algazi), the Angeles Clinic and Research Institute, Los Angeles (O.H.), Stanford University Hospital, Palo Alto (R.P.T.), and the Department of Medical Oncology, City of Hope, Duarte (K.M.) - all in California; Dana-Farber Cancer Institute, Boston (F.S.H., D.A.R.); University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill (S.J.M.); University of Colorado Comprehensive Cancer Center, Aurora (K.L.); University of Michigan, Ann Arbor (C.D.L.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (M.A.P.), Roswell Park Cancer Institute, Buffalo (M.S.E., I.P.), and New York University, Lake Success (A.C.P.) - all in New York; Georgetown-Lombardi Comprehensive Cancer Center, Washington DC (M.B.A.); Winship Cancer Institute of Emory University, Atlanta (R.R.K.); University of Pittsburgh Medical Center, Pittsburgh (A.T.); Bristol-Myers Squibb, Princeton, NJ (J.J., A. Avila, S.D.); and Cleveland Clinic-Taussig Cancer Institute, Cleveland (A.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1805453DOI Listing
August 2018

Engineered T Cells in Synovial Sarcoma: Persistence Pays Off!

Cancer Discov 2018 08;8(8):914-917

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-18-0618DOI Listing
August 2018

PD-1 inhibition in sarcoma still needs investigation - Authors' reply.

Lancet Oncol 2018 01;19(1):e7

Department of Medicine, University of Michigan, Ann Arbor, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30922-1DOI Listing
January 2018

Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.

Melanoma Res 2017 12;27(6):585-590

aDepartment of Internal Medicine, Advocate Medical Group - Oncology North, Park Ridge, Illinois bMelanoma Research Clinic, University of Colorado Cancer Center, Aurora, Colorado cDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia dDepartment of Hematology and Oncology, The University of Arizona Cancer Center, Tucson, Arizona eDepartment of Medicine, Washington University School of Medicine, St Louis, Missouri fDepartment of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee gDepartment of Surgery, Columbia University Medical Center, New York, New York hDepartment of Medical Oncology, Texas Oncology, Dallas, Texas iDepartment of Medicine, Jonsson Comprehensive Cancer Center at University of California jDepartment of Immuno-Oncology, The Angeles Clinic and Research Institute, Los Angeles kDepartment of Oncology, Moores Cancer Center, University of California, San Diego, La Jolla lGenentech Inc., South San Francisco, California mMid Ohio Oncology and Hematology Inc., Columbus, Ohio nDepartment of Melanoma, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC oDepartment of Pathology, University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania pDepartment of Melanoma, Carol G. Simon Cancer Center, Atlantic Health System, Morristown, New Jersey, USA.

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00008390-201712000-0000
Publisher Site
http://dx.doi.org/10.1097/CMR.0000000000000398DOI Listing
December 2017

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute.

J Immunother Cancer 2017 09 19;5(1):74. Epub 2017 Sep 19.

Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-017-0279-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604296PMC
September 2017

Immune Checkpoint Inhibitor Therapy in a Liver Transplant Recipient With Melanoma.

Ann Intern Med 2017 Sep 1;167(5):361-362. Epub 2017 Aug 1.

From The University of Texas MD Anderson Cancer Center, Houston, Texas; Baylor College of Medicine, Houston, Texas; The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7326/L17-0187DOI Listing
September 2017

Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma.

J Immunother Cancer 2017 20;5:45. Epub 2017 Jun 20.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd., Houston, TX 77030 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-017-0250-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477138PMC
January 2018

Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.

J Neurooncol 2017 Jul 12;133(3):595-602. Epub 2017 May 12.

University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-017-2470-4DOI Listing
July 2017

Melanoma Brain Metastases: Current Areas of Investigation and Future Directions.

Cancer J 2017 Jan/Feb;23(1):68-74

From the Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000237DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300745PMC
August 2017

Vaccine therapy + dasatinib for the treatment of patients with stage IIIB-IV melanoma.

Melanoma Manag 2016 Dec 29;3(4):251-254. Epub 2016 Nov 29.

Melanoma Program of the University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt-2016-0016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094598PMC
December 2016

Reply to V. Launay-Vacher, T. Shimokata et al, and C. Porta et al.

J Clin Oncol 2016 07 16;34(20):2430-1. Epub 2016 May 16.

National Cancer Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.2790DOI Listing
July 2016

Immunotherapy in Sarcoma: Future Horizons.

Curr Oncol Rep 2015 Nov;17(11):52

Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-015-0476-7DOI Listing
November 2015

Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies.

J Clin Oncol 2016 Jan 21;34(2):110-6. Epub 2015 Sep 21.

Jan H. Beumer, Fei Ding, Hussein Tawbi, Yan Lin, and Selina L. Chow, University of Pittsburgh Cancer Institute; Jan H. Beumer, University of Pittsburgh School of Pharmacy; Jan H. Beumer and Hussein Tawbi, University of Pittsburgh School of Medicine; Yan Lin, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA; Diana Viluh, Indrani Chatterjee, and Matthew Rinker, Theradex, Princeton, NJ; and S. Percy Ivy, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/09/17/JCO.2014.59
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.59.7302
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.59.7302DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980565PMC
January 2016

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

J Clin Oncol 2016 Mar 14;34(8):786-93. Epub 2015 Sep 14.

George D. Demetri, Dana-Farber Cancer Institute and Ludwig Center at Harvard, Boston, MA; Margaret von Mehren, Fox Chase Cancer Center; Arthur Staddon, University of Pennsylvania, Philadelphia; Hussein Tawbi, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Robin L. Jones, Seattle Cancer Care Alliance, Seattle, WA; Martee L. Hensley, Memorial Sloan Kettering Cancer Center; Robert G. Maki, Mount Sinai Medical Center, New York, NY; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa City, IA; Anthony Elias, University of Colorado Cancer Center, Aurora, CO; Kristen Ganjoo, Stanford Hospital and Clinics, Stanford, CA; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Alexander Spira, Virginia Cancer Specialists, Fairfax, VA; Andrew Dean, St John of God Hospital-Bendat Cancer Centre, Subiaco, Western Australia, Australia; Nushmia Z. Khokhar, Youn Choi Park, Roland E. Knoblauch, and Trilok V. Parekh, Janssen Research & Development, Raritan, NJ; and Shreyaskumar R. Patel, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.62.4734
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.4734DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070559PMC
March 2016

Combination therapies for treating metastatic melanoma.

Authors:
Hussein Tawbi

Clin Adv Hematol Oncol 2015 Apr;13(4):211-4

University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
April 2015

Retinal imaging with en face and cross-sectional optical coherence tomography delineates outer retinal changes in cancer-associated retinopathy secondary to Merkel cell carcinoma.

J Ophthalmic Inflamm Infect 2015 Dec 19;5(1):53. Epub 2015 Aug 19.

Department of Ophthalmology, UPMC Eye Center, Eye and Ear Institute, Ophthalmology and Visual Science Research Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12348-015-0053-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4540718PMC
December 2015

Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma.

PLoS One 2015 6;10(8):e0134426. Epub 2015 Aug 6.

Department of Neurological Surgery, University of Virginia, PO BOX 800212, Charlottesville, VA 22908, United States of America; Neuro-Oncology Branch, National Cancer Institute, NIH, 9030 Old Georgetown Rd, B82/Rm225, Bethesda, MD 20892, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0134426PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527706PMC
May 2016

Immunotherapeutic approaches to sarcoma.

Curr Treat Options Oncol 2015 Jun;16(6):26

Department of Medicine, Division of Hematology/Oncology, School of Medicine, University of Pittsburgh and University of Pittsburgh Cancer Institute, Cancer Pavilion, Suite 569, 5150 Centre Avenue, Pittsburgh, PA, 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-015-0345-5DOI Listing
June 2015

Matching wits with melanoma brain metastases: from biology to therapeutics.

Authors:
Hussein Tawbi

Clin Cancer Res 2014 Nov 18;20(21):5346-8. Epub 2014 Aug 18.

Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. University of Pittsburgh Cancer Institute Melanoma and Skin Cancer Program, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1121DOI Listing
November 2014

Selective BRAF inhibitors make inroads in mutated metastatic melanoma.

Authors:
Hussein Tawbi

J Community Support Oncol 2014 Feb;12(2):46-7

Division of Hematology/Oncology, University of Pittsburgh, PA USA Email:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/jcso.0013DOI Listing
February 2014

Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma.

Oncoimmunology 2014 Jan 27;3(1):e27589. Epub 2014 Feb 27.

Department of Dermatology; University of Pittsburgh School of Medicine; Pittsburgh, PA USA ; Department of Immunology; University of Pittsburgh School of Medicine; Pittsburgh, PA USA ; University of Pittsburgh Cancer Institute; Pittsburgh, PA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.27589DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984268PMC
January 2014

A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.

Clin Cancer Res 2014 Apr 12;20(7):1900-9. Epub 2014 Feb 12.

Authors' Affiliations: Vall d'Hebron Institut d'Oncologia and Universitat Autonoma of Barcelona, Barcelona, Spain; University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; University of Leicester, Leicester, United Kingdom; University Hospital of Zürich, Zürich, Switzerland; Memorial Sloan-Kettering Cancer Center, New York, New York; Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts; and Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1710DOI Listing
April 2014

PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.

Cancer Res 2014 Feb 16;74(4):1045-55. Epub 2013 Dec 16.

Authors' Affiliations: Division of Hematology/Oncology, Department of Medicine; Departments of Immunology and Biostatistics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Pfizer, Cambridge; and Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-2908DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952491PMC
February 2014

Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers.

Cancer Chemother Pharmacol 2014 Jan 30;73(1):207-11. Epub 2013 Oct 30.

Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute, Hillman Research Pavilion, Room G27E, 5117 Centre Avenue, Pittsburgh, PA, 15213-1863, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2337-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880632PMC
January 2014

Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers.

Cancer Chemother Pharmacol 2013 Nov 14;72(5):1143-7. Epub 2013 Sep 14.

Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute, Hillman Research Pavilion, Room G27D, 5117 Centre Avenue, Pittsburgh, PA, 15213-1863, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2283-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818249PMC
November 2013

Melanoma brain metastases: an unmet challenge in the era of active therapy.

Curr Oncol Rep 2013 Oct;15(5):483-91

Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-013-0335-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801214PMC
October 2013

LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma.

J Pharm Biomed Anal 2013 Jul-Aug;81-82:89-98. Epub 2013 Apr 9.

Molecular Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213-1863, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpba.2013.03.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663884PMC
December 2013

Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors.

Cancer Treat Rev 2013 Feb 19;39(1):27-43. Epub 2012 Apr 19.

University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213-1862, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2012.03.007DOI Listing
February 2013

A potential role for nilotinib in KIT-mutated melanoma.

Expert Opin Investig Drugs 2012 Jun 16;21(6):861-9. Epub 2012 Apr 16.

University of Pittsburgh, School of Medicine, Division of Hematology/Oncology, Department of Medicine, Pittsburgh, PA 15232, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/13543784.2012.67
Publisher Site
http://dx.doi.org/10.1517/13543784.2012.679341DOI Listing
June 2012

Improved clinical trial enrollment in adolescent and young adult (AYA) oncology patients after the establishment of an AYA oncology program uniting pediatric and medical oncology divisions.

Cancer 2012 Jul 27;118(14):3614-7. Epub 2011 Dec 27.

Division of Hematology/Oncology, Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center, Pittsburgh, PA 15224, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.26634DOI Listing
July 2012

Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.

J Clin Oncol 2012 Jan 19;30(3):322-8. Epub 2011 Dec 19.

University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center Cancer Pavilion, 5150 Centre Ave, Fifth Fl, Pittsburgh, PA 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.37.5394DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422533PMC
January 2012

Chemotherapy resistance abrogation in metastatic melanoma.

Clin Adv Hematol Oncol 2010 Apr;8(4):259-66

University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA.

View Article

Download full-text PDF

Source
April 2010

Role of histone deacetylases and their inhibitors in cancer biology and treatment.

Curr Clin Pharmacol 2010 Aug;5(3):196-208

University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213-1863, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/157488410791498770DOI Listing
August 2010

Targeted therapy in melanoma.

Biologics 2009 29;3:475-84. Epub 2009 Dec 29.

University of Pittsburgh Cancer, Institute and the University of Pittsburgh School of Medicine, Pittsburg, PA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802073PMC
http://dx.doi.org/10.2147/btt.2009.3637DOI Listing
July 2011